semaglutide what is it for Weight Loss: A Comprehensive Guide Semaglutide – SpringCare Clinic
Description
Among tirzepatide users, the pooled mean on-treatment follow-up was 189 days (median 162 days, IQR 72 to 321 days)
Dulaglutide reduces A1C by an average of 1.1-1.6%
GLP-1 users are defined as patients with an approved claim for at least one of the following GLP-1 medications in the prior 12 months: Mounjaro, Ozempic, Rybelsus, Saxenda, Wegovy, and Zepbound
Non-diabetic patients using GLP-1 therapy typically experience less variability in blood glucose and do not face hypoglycemia risk, simplifying safety monitoring
U.et al (2010)
Cannabis use in relation to obesity and insulin resistance in the Inuit population
